All In Biotech

Drug Trial Radar · NCT07420816

Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder

Phase II Randomized, Multicenter, Double-blind, Doubledummy, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

222

Planned (sponsor's estimate)

Start

Aug 5, 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Apsen Farmaceutica S.A.Industry
Sponsor type
Industry
First posted
Feb 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of APSTZD compared to one active drug and placebo in insomnia treatment.

Conditions

  • Insomnia
  • Insomnia Chronic

Interventions

  • APSTZD 1Drug

    APSTZD + placebo test 2 + placebo test 3 + placebo test 4 + comparator placebo 1

  • APSTZD 2Drug

    APSTZD + placebo test 1 + placebo test 3 + placebo test 4 + comparator placebo 1

  • APSTZD 3Drug

    APSTZD + placebo test 1 + placebo test 2 + placebo test 4 + comparator placebo 1

  • APSTZD 4Drug

    APSTZD + placebo test 1 + placebo test 2 + placebo test 3 + comparator placebo 1

  • Stilnox CR®Drug

    Stilnox CR® + placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4

  • PlaceboDrug

    placebo test 1 + placebo test 2 + placebo test 3 + placebo test 4 + comparator 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction in WASO 6h (Wake After Sleep Onset) assessed by polysomnographyTime frame: Change from baseline after 2 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UNIFAG - Casa Nossa Senhora da PAZ -ASF

    Bragança Paulista, São Paulo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.